Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo

被引:0
|
作者
A Begleiter
M K Leith
J A Thliveris
T Digby
机构
[1] Manitoba Institute of Cell Biology,Department of Internal Medicine
[2] CancerCare Manitoba,Department of Pharmacology and Therapeutics
[3] University of Manitoba,Department of Human Anatomy and Cell Science
[4] Manitoba Institute of Cell Biology,undefined
[5] CancerCare Manitoba,undefined
[6] University of Manitoba,undefined
[7] University of Manitoba,undefined
来源
British Journal of Cancer | 2004年 / 91卷
关键词
mitomycin C; antitumour activity; NQO1; diet; induction;
D O I
暂无
中图分类号
学科分类号
摘要
The bioreductive antitumour agent, mitomycin C (MMC), requires activation by reductive enzymes like NAD(P)H:quinone oxidoreductase 1 (NQO1). We used a novel approach to increase MMC efficacy by selectively inducing NQO1 in tumour cells in vivo. CD-1 nude mice were implanted with HCT116 cells, and fed control diet or diet containing 0.3% of the NQO1 inducer, dimethyl fumarate (DMF). The mice were then treated with saline, 2.0, 3.5 or 2.0 mg kg−1 MMC and dicoumarol, an NQO1 inhibitor. The DMF diet increased NQO1 activity by 2.5-fold in the tumours, but had no effect in marrow cells. Mice given control diet/2.0 mg kg−1 MMC had tumours with the same volume as control mice; however, mice given DMF diet/2.0 mg kg−1 MMC had significantly smaller tumours. Tumour volumes in mice given DMF/2.0 mg kg−1 MMC were similar to those in mice given control diet/3.5 mg kg−1 MMC. Tumour inhibition was partially reversed in mice given DMF/2.0 mg kg−1 MMC and dicoumarol. DMF diet/2.0 mg kg−1 MMC treatment did not increase myelosuppression and did not produce any organ toxicity. These results provide strong evidence that dietary inducers of NQO1 can increase the antitumour activity of bioreductive agents like MMC without increasing toxicity.
引用
收藏
页码:1624 / 1631
页数:7
相关论文
共 50 条
  • [1] Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo
    Begleiter, A
    Leith, MK
    Thliveris, JA
    Digby, T
    BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1624 - 1631
  • [2] Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo
    Tyler Digby
    Marsha K. Leith
    James A. Thliveris
    Asher Begleiter
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 307 - 316
  • [3] Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts:: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo
    Phillips, RM
    Burger, AM
    Fiebig, HH
    Double, JA
    BIOCHEMICAL PHARMACOLOGY, 2001, 62 (10) : 1371 - 1377
  • [4] The correlations between sensitivity to mitomycin C and NQO1 activity in pancreatic cancer cells
    Yoshida, Saori
    Mizuno, Katsushige
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 104P - 104P
  • [5] Kinetics of NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibition by mitomycin C in vitro and in vivo
    Gustafson, DL
    Siegel, D
    Rastatter, JC
    Merz, AL
    Parpal, JC
    Kepa, JK
    Ross, D
    Long, ME
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 305 (03): : 1079 - 1086
  • [6] Interferon γ increases the antitumor activity of mitomycin C against human colon cancer cells in vitro and in vivo
    Ishihara, M
    Kubota, T
    Watanabe, M
    Kawano, Y
    Narai, S
    Yasui, N
    Otani, Y
    Teramoto, T
    Kitajima, M
    ONCOLOGY REPORTS, 1999, 6 (03) : 621 - 625
  • [7] A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C
    Joseph P.
    Jaiswal A.K.
    British Journal of Cancer, 2000, 82 (7) : 1305 - 1311
  • [8] A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C
    Joseph, P
    Jaiswal, AK
    BRITISH JOURNAL OF CANCER, 2000, 82 (07) : 1305 - 1311
  • [9] Evaluation of topoisomerase I and NQO1 gene expression and NQO1 point mutations In patients receiving mitomycin-C and irinotecan.
    Kolesar, J
    Olsen, E
    Drengler, R
    Felton, S
    Schaaf, L
    Von Hoff, D
    Kuhn, J
    Villalona-Calero, M
    CLINICAL CANCER RESEARCH, 2000, 6 : 4512S - 4513S
  • [10] Does NQO1 [NAD(P)H quinone oxidoreductase] genotype influence the response to mitomycin C in superficial bladder tumours?
    Basu, S
    Martin, SW
    Brown, JE
    Loadman, PM
    Flannigan, GM
    Shah, T
    Puri, R
    Phillips, RM
    BRITISH JOURNAL OF CANCER, 2003, 88 : S32 - S32